In a report released today, Terence Flynn from Morgan Stanley maintained a Buy rating on BioNTech SE (BNTX – Research Report), with a price ...

BioNTech (BNTX) stock slid lower today after the German biotechnology company reported its Q4 2024 earnings. The company reported earnings per ...

Q4 2024 Earnings Call Transcript March 10, 2025 Operator: Welcome to BioNTech’s Fourth Quarter and Full-Year 2024 Earnings ...

BioNTech is expanding its oncology pipeline with FixVac, iNeST, and BNT327 for individualized cancer treatments. Read why I ...

Analysts at HC Wainwright issued their FY2024 earnings per share (EPS) estimates for shares of BioNTech in a research report ...

BioNTech (NasdaqGS:BNTX) reported a 2.49% weekly price decline following its announcement of diminished Q4 2024 earnings, where sales and net income significantly dropped compared to the previous year ...

BioNTech has passed on Autolus Therapeutics’ dual targeting CAR-T cell therapy. One year after securing a chance to ...

BioNTech Trading Down 6.6 % NASDAQ:BNTX opened at $98.39 on Wednesday. The company has a 50-day moving average price of $116.45 and a 200-day moving average price of $113.13. The stock has a ...

In this article, we are going to take a look at where BioNTech SE (NASDAQ:BNTX) stands against the other best vaccine stocks to buy now. On February 24, CNBC reported that President Trump declared ...

BioNTech SE BNTX will release its fourth-quarter financial results before the opening bell on Monday, March 10. Analysts expect the Mainz, Germany-based company to report quarterly earnings at 25 ...

Operator Welcome to BioNTech's fourth quarter and full year 2024 earnings call. I would like to hand the call over to Michael Horowicz, director of investor relations. Please go ahead. Michael ...

Welcome to BioNTech's Fourth Quarter and Full-Year 2024 Earnings Call. I would like to hand the call over to Michael Horowicz, Director of Investor Relations. Please go ahead. Thank you.